LaFleur & Godfrey LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 29,767 shares of the medical research company's stock after acquiring an additional 2,488 shares during the quarter. Thermo Fisher Scientific makes up 2.1% of LaFleur & Godfrey LLC's investment portfolio, making the stock its 14th largest position. LaFleur & Godfrey LLC's holdings in Thermo Fisher Scientific were worth $15,486,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC bought a new stake in Thermo Fisher Scientific during the third quarter valued at $26,000. Peterson Financial Group Inc. bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $27,000. Decker Retirement Planning Inc. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $43,000. HWG Holdings LP bought a new position in Thermo Fisher Scientific in the second quarter valued at $50,000. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth about $50,000. Institutional investors own 89.23% of the company's stock.
Insider Transactions at Thermo Fisher Scientific
In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares of the company's stock, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,150 shares of company stock worth $25,954,465. 0.34% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the company. StockNews.com upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Scotiabank initiated coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a "sector perform" rating and a $605.00 target price for the company. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a "buy" rating and a $680.00 price target on the stock. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Finally, Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $648.95.
Get Our Latest Research Report on TMO
Thermo Fisher Scientific Stock Performance
Shares of NYSE:TMO traded down $1.99 during midday trading on Monday, reaching $559.72. 2,134,669 shares of the company's stock traded hands, compared to its average volume of 1,426,114. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The company has a market cap of $214.09 billion, a price-to-earnings ratio of 35.09, a P/E/G ratio of 3.59 and a beta of 0.76. The stock has a 50 day moving average of $529.96 and a 200 day moving average of $568.56. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the previous year, the company posted $5.69 earnings per share. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.
Thermo Fisher Scientific declared that its Board of Directors has authorized a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.
Thermo Fisher Scientific Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.78%.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
